Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 6/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.43 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816161 | 0.88 | MAOB (0.46) | MAOAMAOBHRH3AKR1B1 | |
| SCHEMBL4811875 | 0.85 | PBRM1 (0.41) | PBRM1MAOAMAOBIL4I1PTGS2 | |
| SCHEMBL5175162 | 0.76 | PBRM1 (0.44) | PBRM1MAOAMAOBIL4I1PTGS2 | |
| SCHEMBL1512782 | 0.75 | PBRM1 (0.53) | PBRM1MAOAMAOBIL4I1PTGS2 | |
| SCHEMBL27951808 | 0.75 | PBRM1 (0.50) | PBRM1MAOAMAOBIL4I1HRH3 | |
| SCHEMBL4808718 | 0.75 | PTGS2 (0.40) | PBRM1MAOAMAOBPTGS2 | |
| SCHEMBL4817719 | 0.75 | MAOA (0.32) | MAOAMAOB | |
| SCHEMBL4816674 | 0.74 | MAOB (0.44) | MAOAMAOBPTGS2HRH3 | |
| SCHEMBL4815186 | 0.74 | PTGS2 (0.41) | PBRM1MAOAMAOBPTGS2 | |
| SCHEMBL4807990 | 0.74 | PTGS2 (0.32) | MAOAMAOBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | PBRM1 988/4885MAOA 1625/4885MAOB 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.